151 related articles for article (PubMed ID: 15941387)
1. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.
Guillemard V; Nedev HN; Berezov A; Murali R; Saragovi HU
DNA Cell Biol; 2005 Jun; 24(6):350-8. PubMed ID: 15941387
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
4. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
Guillemard V; Saragovi HU
Cancer Res; 2001 Jan; 61(2):694-9. PubMed ID: 11212270
[TBL] [Abstract][Full Text] [Related]
5. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
6. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
9. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
[TBL] [Abstract][Full Text] [Related]
10. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
11. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
Shukla R; Thomas TP; Peters JL; Desai AM; Kukowska-Latallo J; Patri AK; Kotlyar A; Baker JR
Bioconjug Chem; 2006; 17(5):1109-15. PubMed ID: 16984117
[TBL] [Abstract][Full Text] [Related]
12. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.
Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M
Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783
[TBL] [Abstract][Full Text] [Related]
13. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
[TBL] [Abstract][Full Text] [Related]
14. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.
Berezov A; Zhang HT; Greene MI; Murali R
J Med Chem; 2001 Aug; 44(16):2565-74. PubMed ID: 11472210
[TBL] [Abstract][Full Text] [Related]
15. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
16. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.
Masuda K; Richter M; Song X; Berezov A; Masuda K; Murali R; Greene MI; Zhang H
Oncogene; 2006 Dec; 25(59):7740-6. PubMed ID: 16785990
[TBL] [Abstract][Full Text] [Related]
17. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.
Guillemard V; Uri Saragovi H
Oncogene; 2004 Apr; 23(20):3613-21. PubMed ID: 15034547
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
19. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
